CRP and respiratory failure: Tocilizumab, an IL-6 receptor blocker, is a clinically established therapy that demonstrably improves outcomes in hospitalized patients with rapidly progressing respiratory failure and elevated inflammatory markers such as C-reactive protein (CRP) [169].